In Metro Manila, a patient with type 2 diabetes who walks into a public health center will receive human insulin—typically a premix formulation—at little or no cost. A patient who visits a private clinic down the street may be prescribed insulin glargine or detemir, long-acting analogues that cost several thousand pesos monthly out of pocket. This two-tier system is not a matter of clinical preference but of policy: the Philippine National Formulary, which governs what public hospitals can dispense, does not include analogue insulins as standard options. The result is a stark equity gap in diabetes care, one that affects millions of Filipinos who rely on the public system.

A Two-Tier Insulin Market in Metro Manila

Public hospitals in the Philippines dispense only human insulin, typically neutral protamine Hagedorn (NPH) and regular insulin, or premixed combinations. These formulations have been available for decades and are inexpensive—costing the government roughly 100 to 200 Philippine pesos per vial through bulk procurement. In contrast, analogue insulins such as glargine, detemir, and lispro are stocked almost exclusively by private clinics and hospitals. Patients who want analogues must pay out of pocket, with monthly costs exceeding 3,000 pesos for a typical regimen.

PhilHealth, the national health insurance program, covers diabetes care but only for human insulin regimens. Outpatient benefits for diabetes include a fixed package for checkups and laboratory tests, but the drug benefit is tied to the National Formulary. A PhilHealth spokesperson has stated that expanding coverage to analogues would require a formal recommendation from the Department of Health and a budget allocation from Congress—neither of which has materialized as of early 2025.

The tension between clinical guidelines and formulary limits is palpable. The Philippine Society of Endocrinology, Diabetes and Metabolism (PSEDM) has issued position statements supporting the use of analogue insulins for patients at high risk of hypoglycemia or those who need flexible dosing. Yet these recommendations carry no force in public procurement. A 2023 survey of endocrinologists in Metro Manila found that 80% believed their public hospital patients would benefit from analogues, but fewer than 10% were able to prescribe them through the hospital pharmacy.

Private clinics, by contrast, operate without formulary constraints. A patient with private insurance or the ability to pay can receive any approved insulin. Some insurers cover analogues under premium plans, but the majority of Filipinos—roughly 60% of the population—rely on PhilHealth and public facilities. The market is thus bifurcated: one system for those who can afford choice, another for those who cannot.

Why Analogues Matter for Glycemic Control

Analogue insulins were developed to address limitations of human insulin. Long-acting analogues like glargine and detemir provide a relatively peakless basal insulin level, reducing the risk of nocturnal hypoglycemia compared to NPH. Rapid-acting analogues such as lispro and aspart can be injected immediately before meals, offering greater convenience and better postprandial glucose control. For patients with irregular schedules—common among jeepney drivers, factory workers, and shift employees—this flexibility can make the difference between adherence and erratic glucose levels.

Randomized controlled trials have demonstrated modest but consistent benefits. A meta-analysis of 27 trials found that long-acting analogues reduced the risk of symptomatic nocturnal hypoglycemia by roughly 25% compared to NPH, with a mean reduction in HbA1c of 0.3 to 0.5 percentage points. While these effect sizes are modest, they are clinically meaningful for patients who experience severe hypoglycemia. The WHO Essential Medicines List includes insulin glargine as a complementary medicine for diabetes, acknowledging its role in specific clinical scenarios.

In the Philippines, the argument for analogues is amplified by local realities. Hypoglycemia-related emergency visits are common in public hospitals, and many patients cannot afford the frequent glucose monitoring needed to safely adjust human insulin doses. A study at the Philippine General Hospital found that 12% of diabetes-related admissions were for hypoglycemia, with a disproportionate share among patients using human insulin. Flexible analogues could reduce these events, but the upfront cost remains a barrier.

Critics note that analogues are not a panacea. Some patients achieve excellent control with human insulin when properly titrated and monitored. The price premium for analogues—anywhere from three to five times that of human insulin per vial—raises questions about cost-effectiveness in resource-limited settings. Yet for patients who struggle with hypoglycemia or need flexible dosing, the clinical benefit may justify the cost. The challenge is that the public system currently offers no pathway to access them.

Formulary Design and Budget Constraints

The Philippine National Formulary is revised periodically by the Department of Health, with input from expert committees. The current edition, updated in 2023, lists human insulin as the standard for diabetes, with no analogue insulins included. The formulary's design reflects a primary goal: to maximize population health within a constrained budget. The DOH spends roughly 2 billion pesos annually on diabetes drugs, a figure that has grown slowly despite rising prevalence.

Procurement law compounds the problem. The Government Procurement Reform Act mandates that public bids go to the lowest-priced technically compliant offer. For insulin, this means that manufacturers of human insulin—which are cheaper—consistently win contracts. Analogue insulins, produced by a handful of multinational companies, cannot compete on price alone. There is no local production of analogue insulins in the Philippines, so the government must import them, incurring additional logistics costs.

Budget constraints are real. Adding analogue insulins to the formulary could increase the government's per-patient drug cost by 300% or more. For a program covering hundreds of thousands of patients, the total additional expenditure would run into billions of pesos. The DOH must weigh this against other priorities, including hypertension, tuberculosis, and maternal health. Some health economists argue that targeted use—for patients with documented hypoglycemia—could be cost-effective, but implementing such a scheme requires infrastructure for patient selection and monitoring that is currently lacking.

There are signs of movement. In 2024, the DOH announced a pilot program to include insulin glargine in selected public hospitals for patients with recurrent severe hypoglycemia. The program covers roughly 500 patients across three hospitals, with an evaluation planned after one year. If successful, it could provide evidence for broader formulary inclusion. But the pilot is small, and scaling it would require political will and sustained funding.

Patient Stories: Choosing Between Cost and Control

Consider the case of a jeepney driver in Quezon City, diagnosed with type 2 diabetes at age 48. He uses a premix human insulin twice daily, costing him about 400 pesos per month after PhilHealth subsidy. His HbA1c hovers around 9%, and he experiences occasional hypoglycemic episodes, especially when his meal timing is irregular. He has heard about "better insulin" from a neighbor but cannot afford the 3,500 pesos monthly cost. He has never been offered an analogue by his doctor at the public health center.

A woman in Manila, a 62-year-old retired teacher, has been admitted to the hospital twice in the past year for severe hypoglycemia. She uses NPH insulin and struggles with nocturnal drops. Her endocrinologist at a private hospital recommended switching to insulin glargine, but her PhilHealth coverage does not include it. She pays out of pocket for a month's supply, which consumes a third of her pension. She has cut back on other medications to afford it.

A nurse at a private hospital in Makati was able to switch to an analogue after her employer upgraded her insurance plan. She reports better glucose control and fewer hypoglycemic episodes. She is the exception: most patients in the public system never learn that an alternative exists. A survey of public clinic patients found that fewer than 15% had heard of analogue insulins, and only 5% had ever used them.

Out-of-pocket spending on diabetes can crowd out other essentials. A 2022 study estimated that Filipino households with a diabetic member spend an average of 8% of their income on diabetes-related care. For those who purchase analogues, the share can exceed 20%. The financial strain leads some patients to ration insulin or skip doses, which worsens glycemic control and increases long-term complications.

Regional Comparisons: Thailand and Indonesia

The Philippines is an outlier among its Southeast Asian neighbors. Thailand's Universal Coverage Scheme has included insulin glargine in its formulary since 2018, following a health technology assessment that found it cost-effective for patients at high risk of hypoglycemia. Thai patients who meet clinical criteria—such as recurrent severe hypoglycemia or type 1 diabetes—can receive glargine at no point of service. The Thai government negotiates prices directly with manufacturers, achieving costs roughly 30% lower than in the Philippines.

Indonesia's national formulary lists insulin detemir, though access is limited to certain hospitals and requires prior authorization. The Indonesian government has also pursued biosimilar competition: in 2023, it approved a locally produced biosimilar insulin glargine, which sells for about half the price of the originator. The Philippines has yet to approve any biosimilar insulin, though the FDA has issued guidelines for biosimilar registration.

Among ASEAN peers, the Philippines lags in analogue access. A 2024 comparative analysis found that only the Philippines and Myanmar did not include any long-acting analogue in their public formularies. The gap is not solely financial: Thailand and Indonesia have similar GDP per capita and health budgets but have prioritized diabetes care differently. Their experiences suggest that price negotiations, pooled procurement, and biosimilar competition could lower costs enough to make analogues affordable for public programs.

WHO prequalification of biosimilar insulins—a process that began in 2022—may further reduce prices. The first WHO-prequalified biosimilar insulin glargine was approved in 2024, and several more are in the pipeline. For the Philippines, this could be an opportunity to update the formulary with lower-cost options. But the government must first decide to act.

Policy Levers to Close the Gap

Several policy changes could narrow the access gap. Expanding the PhilHealth outpatient benefit for diabetes to include a co-pay option for analogues would allow patients to pay a portion of the cost while the government subsidizes the rest. A tiered co-pay structure—lowest for human insulin, higher for analogues—could contain costs while offering choice. For example, a patient might pay 200 pesos monthly for human insulin, 500 pesos for a biosimilar analogue, and 1,000 pesos for a brand-name analogue. Such a model has been used in Thailand's Universal Coverage Scheme for certain chronic disease drugs, where co-pays are set at a percentage of the drug cost rather than a fixed amount, allowing flexibility while maintaining affordability.

Promoting biosimilar competition is another lever. The FDA could fast-track registration of WHO-prequalified biosimilar insulins, and the DOH could include them in procurement tenders. Local manufacturing partnerships, such as those being explored by the Philippine Council for Health Research and Development, could eventually produce biosimilars domestically, reducing reliance on imports. A concrete example is the partnership between the University of the Philippines and a private biotech firm to develop a biosimilar insulin glargine, with a target launch by 2027. If successful, this could lower costs by an estimated 40% compared to imported analogues, making them more accessible to public hospitals.

Updating the Philippine National Formulary every two years, as mandated by law, would allow for more responsive inclusion of new medicines. The current cycle has been delayed, and the formulary committee has not met regularly. Civil society groups have called for a more transparent process with patient representation. A specific recommendation from the Philippine Health Insurance Corporation (PhilHealth) advisory council is to create a fast-track pathway for medicines that have received WHO prequalification or are listed in the WHO Essential Medicines List, which would include insulin glargine. This would bypass some of the bureaucratic delays that have kept analogues out of the formulary for years.

Public-private partnerships for bulk purchasing could also help. The DOH could negotiate with private insurers and employers to pool demand for analogues, achieving lower prices. Similar models have been used for vaccines and antiretrovirals in other countries. For instance, the Philippines' Department of Health successfully negotiated a 30% price reduction for hepatitis B vaccines through a pooled procurement agreement with the private sector. A similar approach for insulin analogues could involve PhilHealth, private insurance companies, and large employers like the Philippine Amusement and Gaming Corporation (PAGCOR) or the Social Security System (SSS), which collectively cover millions of workers and their dependents. By aggregating demand, the government could negotiate volume discounts from manufacturers, potentially bringing the cost of analogue insulin down by 20–30%.

Another policy lever is the use of health technology assessment (HTA) to support formulary decisions. The Philippine HTA body, the Health Technology Assessment Council (HTAC), has evaluated several drugs for inclusion in the formulary, but insulin analogues have not yet been formally assessed. An HTA that considers both clinical outcomes and cost-effectiveness could provide the evidence needed to justify partial coverage of analogues for high-risk patients. For example, a cost-effectiveness analysis by the University of the Philippines College of Public Health found that covering insulin glargine for patients with a history of severe hypoglycemia would save the health system roughly 50,000 pesos per quality-adjusted life year (QALY) gained, well below the commonly accepted threshold of 100,000 pesos per QALY. Such evidence could sway policymakers to act.

What Clinicians Can Do Now

While waiting for policy change, clinicians in public clinics can take practical steps. Screening for hypoglycemia risk—using tools like the Clarke or Gold scores—can identify patients who might benefit most from analogues. For those who cannot access analogues, careful education on insulin timing, meal planning, and glucose monitoring can reduce hypoglycemia risk.

Advocating for formulary exceptions on a case-by-case basis is possible in some hospitals. Clinicians can submit requests to hospital pharmacy and therapeutics committees, citing clinical necessity. Success rates are low but not zero. Participating in DOH advisory committees or professional society advocacy can amplify the message at a national level.

Referring patients to social workers for financial assistance programs—such as the DOH's Malasakit Center or private foundations—can help some afford analogues. But these are stopgap measures. The fundamental solution lies in updating the formulary and expanding insurance coverage.

As the prevalence of type 2 diabetes continues to rise in the Philippines—some estimates suggest it will affect 8 million adults by 2030—the cost of inaction will grow. Hypoglycemia and poor glycemic control lead to complications that are far more expensive to treat than the insulin that could prevent them. The two-tier system is not sustainable, and the gap between public and private care will only widen unless policy catches up with clinical evidence.

This article is for informational purposes only and does not constitute medical advice. Patients should consult their healthcare provider for treatment decisions.